Breaking News, Collaborations & Alliances

Delnova, Pace Life Sciences Partner on ReViVox Development

Will support clinical development of DelNova’s lead candidate ReViVox to reverse unwanted paralysis induced by BoNTs such as Botox.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

DelNova has entered a partnership with Pace Life Sciences to serve as its contract development and manufacturing organization. The partnership will support clinical development of DelNova’s lead candidate ReViVox for the rescue of undesirable outcomes which may arise from a botulinum neurotoxin (BoNT) treatment such as Botox. Pace Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, and regulatory compliance, services to the biopharmaceutical ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters